A fundamental analysis of Alembic Pharma (APLLTD) covering revenue trends, profitability, valuation, and shareholding patterns.
Alembic Pharma Revenue Trend
Revenue rose 10.1% to ₹7,345 Cr in FY2026 for Alembic Pharma, against ₹6,672 Cr the year before.
Stepping back, the 10-year revenue CAGR of 8.8% shows Alembic Pharma has been growing at a moderate, sustainable pace.
In terms of scale, Alembic Pharma's ₹7,345 Cr in annual revenue positions it as a mid-sized pharmaceuticals company.
Alembic Pharma has posted revenue growth for 4 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹7,345 Cr | +10.1% |
| FY2025 | ₹6,672 Cr | +7.1% |
| FY2024 | ₹6,229 Cr | +10.1% |
| FY2023 | ₹5,655 Cr | +5.6% |
| FY2022 | ₹5,356 Cr | — |
View Alembic Pharma's full 10-year revenue trend with CAGR analysis →
Alembic Pharma Profitability
At ₹675 Cr, Alembic Pharma's FY2026 net profit was 15.9% ahead of FY2025.
Not much change on the margin front — net profit margin held at roughly 9.2% in FY2026.
The diluted EPS figure moved up to ₹34.33 in FY2026, against ₹29.68 posted in FY2025.
Is Alembic Pharma Undervalued
Alembic Pharma shares are currently trading at ₹805.75.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Alembic Pharma Shareholding Pattern
Promoters haven't moved — their 69.9% holding has been unchanged for 4 quarters.
Foreign institutions moved their stake up to 4.2% from 4.0% over the past year.
On the domestic institutional side, the holding is 15.9% as of June 2026 — down from 16.3%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 69.9% | 4.2% | 15.9% | 10.0% |
| Mar 2026 | 69.7% | 4.2% | 16.2% | 9.8% |
| Dec 2025 | 69.7% | 4.2% | 16.2% | 9.8% |
| Sep 2025 | 69.7% | 4.0% | 16.3% | 9.9% |
Track quarterly shareholding changes for Alembic Pharma →
Alembic Pharma Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2026, the total asset base came in at ₹87.63B, up 12.7% YoY from ₹77.73B.
Property, Plant & Equipment accounts for 39.7% of the total, ahead of Inventories (28.7%) and Receivables (16.7%).
Capital structure: 64.7% equity, 16.3% debt, 19.0% operating liabilities. Over the year, debt is up 13.7% and equity is up 9.2%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 2.03B |
| Receivables | 14.66B |
| Inventories | 25.11B |
| Property, Plant & Equipment | 34.77B |
| Investments | 1.41B |
| Intangibles & Goodwill | 2.37B |
| Other Assets | 7.28B |
| Category | Value |
|---|---|
| Equity | 56.69B |
| Short-term Debt | 12.63B |
| Long-term Debt | 1.67B |
| Trade Payables | 8.35B |
| Other Liabilities | 8.29B |
What Stands Out About Alembic Pharma
What should investors take away from Alembic Pharma's (APLLTD) latest numbers? Here's the summary.
Revenue of ₹7,345 Cr in FY2026, up 10.1% year-over-year.
Long-term revenue has been compounding at 8.8% annually over 10 years.
The company is profitable, with a net margin of 9.2% and net income of ₹675 Cr.
Unlock Full Analysis
Craytheon's full analysis of Alembic Pharma goes deeper: three valuation models, growth metrics, and 10 years of financial data.